Jonah J. C. Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jonah J. C. Thomas has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Pratik Choudhary
Diabetes Research Centre University of Leicester Leicester UK
6 shared publications - Amanda Jane Daley
Centre for Lifestyle Medicine and Behaviour, School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK
5 shared publications - Dale W. Esliger
School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK
5 shared publications - James P. Sanders
Centre for Lifestyle Medicine and Behaviour, School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK
5 shared publications - Julia Katharina Mader
Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria
4 shared publications - Kajal Gokal
Centre for Lifestyle Medicine and Behaviour, School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK
3 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Wiley in Diabetic Medicine
Impact of acute hyperglycaemia on cognitive function in people with diabetes: A systematic review
Aims: While the effect of short‐term hypoglycaemia on cognitive function has been widely studied, the impact of acute hyperglycaemia on cognitive performance in people with diabetes is poorly understood. This systematic review summarised evidence on the effect of acute hyperglycaemia on cognitive functioning. Methods: Searches were conducted in MEDLINE, Embase, CINAHL, PsycINFO from conception to 5th March 2025. People with type 1 diabetes (T1D), type 2 diabetes (T2D) or control participants were included. Studies with the main outcome of dementia were excluded. A narrative synthesis was undertaken. Results: Eighteen studies were included, involving children and adults with T1D and T2D, using observational and experimental designs. Findings were synthesised by cognitive function domain: attention, processing speed, executive functioning, working memory and study design. Two studies measured driving performance. At blood glucose of 10–15 mmol/L the effects were mixed. At a blood glucose of 15–18 mmol/L impairment was more consistent. Driving performance in young adults with T1D was impaired at >16.7 mmol/L. At glucose ≥20 mmol/L, most studies reported widespread cognitive impairment in especially working memory, attention and processing speed. Conclusions: Acute hyperglycaemia impairs cognitive functioning in people living with diabetes, with effects generally increasing at higher glucose levels. Whilst this pattern was not uniform across all blood glucose ranges and cognitive domains, impairment in cognitive function could impact on everyday activities for adults and children, including schoolwork, driving and work productivity. Future research should focus on crossover or clamp studies to clarify thresholds and evaluate real‐world outcomes.
- 18 November 2026
- Published by Wiley in Diabetic Medicine
Open AccessImpact of acute hyperglycaemia on cognitive function in people with diabetes: A systematic review
Aims: While the effect of short‐term hypoglycaemia on cognitive function has been widely studied, the impact of acute hyperglycaemia on cognitive performance in people with diabetes is poorly understood. This systematic review summarised evidence on the effect of acute hyperglycaemia on cognitive functioning. Methods: Searches were conducted in MEDLINE, Embase, CINAHL, PsycINFO from conception to 5th March 2025. People with type 1 diabetes (T1D), type 2 diabetes (T2D) or control participants were included. Studies with the main outcome of dementia were excluded. A narrative synthesis was undertaken. Results: Eighteen studies were included, involving children and adults with T1D and T2D, using observational and experimental designs. Findings were synthesised by cognitive function domain: attention, processing speed, executive functioning, working memory and study design. Two studies measured driving performance. At blood glucose of 10–15 mmol/L the effects were mixed. At a blood glucose of 15–18 mmol/L impairment was more consistent. Driving performance in young adults with T1D was impaired at >16.7 mmol/L. At glucose ≥20 mmol/L, most studies reported widespread cognitive impairment in especially working memory, attention and processing speed. Conclusions: Acute hyperglycaemia impairs cognitive functioning in people living with diabetes, with effects generally increasing at higher glucose levels. Whilst this pattern was not uniform across all blood glucose ranges and cognitive domains, impairment in cognitive function could impact on everyday activities for adults and children, including schoolwork, driving and work productivity. Future research should focus on crossover or clamp studies to clarify thresholds and evaluate real‐world outcomes.
- Open Access
- 5 November 2026
- Published by Springer Nature in Diabetologia
- p. 1-13
Real-world evidence for decisions in diabetes
- 5 November 2026
- Published by Springer Nature in Diabetologia
- p. 1-13
Open AccessReal-world evidence for decisions in diabetes
- Open Access
- 3 November 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Exploring Corresponding Cutpoints for Hypoglycaemia Awareness Questionnaire ( HypoA ‐Q) Impaired Awareness Subscale in Relation to the Gold and Clarke Measures: A Post Hoc Analysis From the Hypo‐ METRICS Study
Aims: The Hypoglycaemia Awareness Questionnaire–Impaired Awareness subscale (HypoA‐Q/IA) was developed to enhance impaired awareness of hypoglycaemia (IAH) assessment, addressing methodological deficiencies of the established Gold and Clarke measures. An IAH cutpoint (HypoA‐Q/IA ≥ 12) was identified from a clamp study in Type 1 diabetes (T1D). We explored cutpoints in relation to Gold and Clarke measures, and their co‐occurrence, in the larger, real‐world observational Hypo‐METRICS study, in people with T1D (pwT1D) and insulin‐treated Type 2 diabetes (pwT2D). Material and Methods: Hypo‐METRICS recruited pwT1D or pwT2D with ≥ 1 hypoglycaemic event in the previous 3 months. IAH was defined as Gold ≥ 4, Clarke ≥ 4 and/or HypoA‐Q/IA ≥ 12. Bidirectional ROC analysis was performed between HypoA‐Q/IA and Gold/Clarke cutpoints. Results: Questionnaires were completed by 232 pwT1D and 285 pwT2D (male 47% vs. 62%, p < 0.001; median age 49 vs. 63 years, p < 0.001; HbA1c 7.3% vs. 7.4%, p = 0.03). IAH prevalence was 24% by Gold ≥ 4, 16% by Clarke ≥ 4 and 7% by HypoA‐Q/IA ≥ 12. ROC analysis yielded HypoA‐Q/IA cutpoints of ≥ 7 against Gold ≥ 4 (AUC 0.87) and ≥ 9 against Clarke ≥ 4 (AUC 0.89), and cutpoints of Gold ≥ 4 (AUC 0.87) and Clarke ≥ 3 (AUC 0.93) against HypoA‐Q/IA ≥ 12. Of those with IAH by either measure, 24% were identified by both HypoA‐Q/IA ≥ 12 and Gold ≥ 4, and 32% by both HypoA‐Q/IA ≥ 12 and Clarke ≥ 4, with lower overlap in T2D than T1D. Conclusions: HypoA‐Q/IA cutpoints corresponding to legacy IAH cutpoints (≥ 7–9) were lower than the clamp‐derived threshold (≥ 12), suggesting ≥ 12 may identify a subgroup with more severe IAH. These cutpoints enable cross‐study comparison; prospective validation against severe hypoglycaemia risk is needed.
- 3 November 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Open AccessExploring Corresponding Cutpoints for Hypoglycaemia Awareness Questionnaire ( HypoA ‐Q) Impaired Awareness Subscale in Relation to the Gold and Clarke Measures: A Post Hoc Analysis From the Hypo‐ METRICS Study
Aims: The Hypoglycaemia Awareness Questionnaire–Impaired Awareness subscale (HypoA‐Q/IA) was developed to enhance impaired awareness of hypoglycaemia (IAH) assessment, addressing methodological deficiencies of the established Gold and Clarke measures. An IAH cutpoint (HypoA‐Q/IA ≥ 12) was identified from a clamp study in Type 1 diabetes (T1D). We explored cutpoints in relation to Gold and Clarke measures, and their co‐occurrence, in the larger, real‐world observational Hypo‐METRICS study, in people with T1D (pwT1D) and insulin‐treated Type 2 diabetes (pwT2D). Material and Methods: Hypo‐METRICS recruited pwT1D or pwT2D with ≥ 1 hypoglycaemic event in the previous 3 months. IAH was defined as Gold ≥ 4, Clarke ≥ 4 and/or HypoA‐Q/IA ≥ 12. Bidirectional ROC analysis was performed between HypoA‐Q/IA and Gold/Clarke cutpoints. Results: Questionnaires were completed by 232 pwT1D and 285 pwT2D (male 47% vs. 62%, p < 0.001; median age 49 vs. 63 years, p < 0.001; HbA1c 7.3% vs. 7.4%, p = 0.03). IAH prevalence was 24% by Gold ≥ 4, 16% by Clarke ≥ 4 and 7% by HypoA‐Q/IA ≥ 12. ROC analysis yielded HypoA‐Q/IA cutpoints of ≥ 7 against Gold ≥ 4 (AUC 0.87) and ≥ 9 against Clarke ≥ 4 (AUC 0.89), and cutpoints of Gold ≥ 4 (AUC 0.87) and Clarke ≥ 3 (AUC 0.93) against HypoA‐Q/IA ≥ 12. Of those with IAH by either measure, 24% were identified by both HypoA‐Q/IA ≥ 12 and Gold ≥ 4, and 32% by both HypoA‐Q/IA ≥ 12 and Clarke ≥ 4, with lower overlap in T2D than T1D. Conclusions: HypoA‐Q/IA cutpoints corresponding to legacy IAH cutpoints (≥ 7–9) were lower than the clamp‐derived threshold (≥ 12), suggesting ≥ 12 may identify a subgroup with more severe IAH. These cutpoints enable cross‐study comparison; prospective validation against severe hypoglycaemia risk is needed.
- Open Access
- 16 October 2026
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 42 (7) , e70241
Real‐World Databases in Diabetes: A Systematic Review
Aim: To identify publications that describe RWD databases in the field of diabetes and map their key characteristics. Methods: Databases were searched (MEDLINE, SCOPUS, CINAHL from January 2018 to October 2025) to identify relevant publications describing RWD databases. Eligible studies were identified as RWD databases that contained more than 1000 adults and were followed up for one year or longer. Metadata including population, sample size, and outcomes were then extracted. Results: A total of 610 eligible RWD databases were identified from 1779 included articles. Databases were identified in 74 countries, with the majority collected in Europe ( n = 193). Only 22 databases were identified in lower‐ and‐ middle income countries (as defined by the World Bank). Demographics, prescription, diagnosis, and biochemical information were collected frequently; however, mortality and technology related variables (CGM usage) were found in fewer datasets. Very few databases were open access however 205 mentioned having the possibility for data sharing. Conclusion: We have produced an online dashboard to summarise the RWD databases available in the field of diabetes. We found many RWD databases globally that contain a range of variables related to individuals' health; however, lower‐ and middle‐income nations are underrepresented within these data.
- 16 October 2026
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 42 (7) , e70241
Open AccessReal‐World Databases in Diabetes: A Systematic Review
Aim: To identify publications that describe RWD databases in the field of diabetes and map their key characteristics. Methods: Databases were searched (MEDLINE, SCOPUS, CINAHL from January 2018 to October 2025) to identify relevant publications describing RWD databases. Eligible studies were identified as RWD databases that contained more than 1000 adults and were followed up for one year or longer. Metadata including population, sample size, and outcomes were then extracted. Results: A total of 610 eligible RWD databases were identified from 1779 included articles. Databases were identified in 74 countries, with the majority collected in Europe ( n = 193). Only 22 databases were identified in lower‐ and‐ middle income countries (as defined by the World Bank). Demographics, prescription, diagnosis, and biochemical information were collected frequently; however, mortality and technology related variables (CGM usage) were found in fewer datasets. Very few databases were open access however 205 mentioned having the possibility for data sharing. Conclusion: We have produced an online dashboard to summarise the RWD databases available in the field of diabetes. We found many RWD databases globally that contain a range of variables related to individuals' health; however, lower‐ and middle‐income nations are underrepresented within these data.
- Open Access
- 31 March 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 236, 113220
Meeting time in range and time below range targets is not associated with psychological outcomes in type 1 or insulin-treated type 2 diabetes in the Hypo-METRICS study
- 31 March 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 236, 113220
Open AccessMeeting time in range and time below range targets is not associated with psychological outcomes in type 1 or insulin-treated type 2 diabetes in the Hypo-METRICS study
- Open Access
- 23 January 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (3) , e70194
Associations between impaired awareness of hypoglycaemia and mental health in insulin‐treated type 2 and type 1 diabetes in the Hypo‐ METRICS study
Aims: The mental health impact of impaired awareness of hypoglycaemia (IAH) in people with type 2 diabetes (T2D) is not known. We explored this in people with insulin‐treated T2D and type 1 diabetes (T1D). Methods: Hypo‐METRICS was a 10‐week cross‐sectional observation of hypoglycaemia experience, collecting data on glucose and activity. Participants (325 insulin‐treated T2D, 277 T1D) completed questionnaires scoring depression (PHQ‐9), anxiety (GAD‐7), diabetes distress (PAID) and fear of hypoglycaemia (HFS‐II [worry]) at baseline. IAH was defined as a Gold score ≥4. Relationships between IAH and mental health scores were explored using unadjusted and adjusted generalised linear regression analyses. Age, sex, race, diabetes duration, level of education, employment status, continuous glucose monitoring (CGM) use, hypoglycaemia, use of anti‐depressants and use of anti‐anxiety medications were covariates in the adjusted regression. Results: In unadjusted regression in insulin‐treated T2D, IAH was associated with higher PHQ‐9 (6.4% [1.5%–11.3%]; p = 0.011), GAD‐7 (7.6% [2.1%–13%]; p = 0.006) and HFS‐II (worry) (7.4% [2.8%–12%]; p = 0.002) scores, with no differences in PAID ( p = 0.655). After adjustment, IAH was associated with higher HFS‐II (worry) (5.3% [0.3%–10.6%]; p = 0.048) only. In T1D, IAH was associated with higher PHQ‐9 (6.2% [1.3%–10.8%]; p = 0.012), GAD‐7 (6.1% [0.1%–12.2%]; p = 0.046) and HFS‐II (worry) (6.1% [0.06%–11.5%]; p = 0.029) scores, but not PAID ( p = 0.654), all unadjusted. These relationships remained after adjustment, which also showed higher PAID (8.43% [2.62%–14.24%]; p = 0.005). Conclusion: Our data demonstrated associations between IAH and a greater mental health burden in both insulin‐treated T2D and T1D. Addressing these mental health challenges should be an important part of the holistic care of people with IAH and insulin‐treated diabetes.
- 23 January 2026
- Published by Wiley in Diabetic Medicine
- Vol. 43 (3) , e70194
Open AccessAssociations between impaired awareness of hypoglycaemia and mental health in insulin‐treated type 2 and type 1 diabetes in the Hypo‐ METRICS study
Aims: The mental health impact of impaired awareness of hypoglycaemia (IAH) in people with type 2 diabetes (T2D) is not known. We explored this in people with insulin‐treated T2D and type 1 diabetes (T1D). Methods: Hypo‐METRICS was a 10‐week cross‐sectional observation of hypoglycaemia experience, collecting data on glucose and activity. Participants (325 insulin‐treated T2D, 277 T1D) completed questionnaires scoring depression (PHQ‐9), anxiety (GAD‐7), diabetes distress (PAID) and fear of hypoglycaemia (HFS‐II [worry]) at baseline. IAH was defined as a Gold score ≥4. Relationships between IAH and mental health scores were explored using unadjusted and adjusted generalised linear regression analyses. Age, sex, race, diabetes duration, level of education, employment status, continuous glucose monitoring (CGM) use, hypoglycaemia, use of anti‐depressants and use of anti‐anxiety medications were covariates in the adjusted regression. Results: In unadjusted regression in insulin‐treated T2D, IAH was associated with higher PHQ‐9 (6.4% [1.5%–11.3%]; p = 0.011), GAD‐7 (7.6% [2.1%–13%]; p = 0.006) and HFS‐II (worry) (7.4% [2.8%–12%]; p = 0.002) scores, with no differences in PAID ( p = 0.655). After adjustment, IAH was associated with higher HFS‐II (worry) (5.3% [0.3%–10.6%]; p = 0.048) only. In T1D, IAH was associated with higher PHQ‐9 (6.2% [1.3%–10.8%]; p = 0.012), GAD‐7 (6.1% [0.1%–12.2%]; p = 0.046) and HFS‐II (worry) (6.1% [0.06%–11.5%]; p = 0.029) scores, but not PAID ( p = 0.654), all unadjusted. These relationships remained after adjustment, which also showed higher PAID (8.43% [2.62%–14.24%]; p = 0.005). Conclusion: Our data demonstrated associations between IAH and a greater mental health burden in both insulin‐treated T2D and T1D. Addressing these mental health challenges should be an important part of the holistic care of people with IAH and insulin‐treated diabetes.
- 1 January 2026
- Published by Human Kinetics in Journal for the Measurement of Physical Behaviour
- Vol. 9 (1)
Translating Daily Step Count Targets From Research-Grade Approaches to a Consumer Wearable
Background : Consumer wearables enable people to monitor daily step counts, yet most evidence on step counts and health is currently derived from waist-worn research-grade accelerometers. How step counts from consumer devices correspond to those derived from research-grade methods remains unclear. We compared step counts from a wrist-worn consumer device with those estimated from multiple research-grade accelerometers, wear sites, and algorithms. Methods : Participants concurrently wore a Fitbit Charge 5 on the nondominant wrist and four research-grade accelerometers for up to 4 days: an ActiGraph (waist), two GENEActiv devices (both wrists), and an activPAL (thigh). Step counts were generated from proprietary algorithms (Fitbit, ActiGraph, and activPAL) and nonproprietary algorithms (GENEActiv: OxWearables, Verisense; activPAL: ActiPASS). Daily step counts were compared using mean absolute percentage error, intraclass correlations, limits of agreement, and standardized major axis regression analysis. Results : Twenty-nine participants (62% female, mean age [SD] = 39 [11] years) recorded 84 valid days across all devices. The Fitbit estimated a median of 10,231 (8331, 14,348) (median (Q1, Q3)) steps/day, while most research-grade methods were ∼500–2,000 steps/days lower with wide limits of agreement. Intraclass correlations suggested moderate consistency with research-grade step counts (.68–.76). Standardized major axis regression indicated that 7,000 Fitbit steps corresponded to between ∼5,400 (waist-worn ActiGraph) and ∼7,900 (dominant-wrist GENEActiv Verisense algorithm) steps/day. Conclusions : Step counts vary by device, wear site, and/or algorithm. The wrist-worn Fitbit recorded higher step counts than waist-worn research-grade methods, which may lead to people inadvertently undershooting step targets. Consideration of methodological differences is essential when translating research-derived step targets to public health recommendations.
- 1 January 2026
- Published by Human Kinetics in Journal for the Measurement of Physical Behaviour
- Vol. 9 (1)
Translating Daily Step Count Targets From Research-Grade Approaches to a Consumer Wearable
Background : Consumer wearables enable people to monitor daily step counts, yet most evidence on step counts and health is currently derived from waist-worn research-grade accelerometers. How step counts from consumer devices correspond to those derived from research-grade methods remains unclear. We compared step counts from a wrist-worn consumer device with those estimated from multiple research-grade accelerometers, wear sites, and algorithms. Methods : Participants concurrently wore a Fitbit Charge 5 on the nondominant wrist and four research-grade accelerometers for up to 4 days: an ActiGraph (waist), two GENEActiv devices (both wrists), and an activPAL (thigh). Step counts were generated from proprietary algorithms (Fitbit, ActiGraph, and activPAL) and nonproprietary algorithms (GENEActiv: OxWearables, Verisense; activPAL: ActiPASS). Daily step counts were compared using mean absolute percentage error, intraclass correlations, limits of agreement, and standardized major axis regression analysis. Results : Twenty-nine participants (62% female, mean age [SD] = 39 [11] years) recorded 84 valid days across all devices. The Fitbit estimated a median of 10,231 (8331, 14,348) (median (Q1, Q3)) steps/day, while most research-grade methods were ∼500–2,000 steps/days lower with wide limits of agreement. Intraclass correlations suggested moderate consistency with research-grade step counts (.68–.76). Standardized major axis regression indicated that 7,000 Fitbit steps corresponded to between ∼5,400 (waist-worn ActiGraph) and ∼7,900 (dominant-wrist GENEActiv Verisense algorithm) steps/day. Conclusions : Step counts vary by device, wear site, and/or algorithm. The wrist-worn Fitbit recorded higher step counts than waist-worn research-grade methods, which may lead to people inadvertently undershooting step targets. Consideration of methodological differences is essential when translating research-derived step targets to public health recommendations.
- Open Access
- 1 October 2025
- Published by Wiley in Diabetic Medicine
- Vol. 42 (11) , e70112
A cohort description and comparison of four European national diabetes registries for the REDDIE project
Aims: The Real‐world Evidence for Decisions in Diabetes (REDDIE) project aims to better understand how to use real‐world data (RWD) to advance research related to diabetes. To achieve this aim, four national registries (National Diabetes Audit (NDA (England)), Diabetes Patienten Verlaufsdokumentation (DPV (Germany)), Swedish National Registries (NDR), Danish National Registries (DNR)) are contributing data to the REDDIE project. This publication aims to describe the four registries and compare their unique strengths and limitations. Methods: Data regarding the four registries were extracted from their inception until 2024. Data regarding demographics, prescriptions, outcomes, lifestyle and diabetes‐specific variables (usage of continuous glucose monitors) were summarised. Results: A core set of variables was identified across all four registries in the REDDIE project. Demographic information, diabetes‐related medication, measures of glycaemic control and lifestyle factors are measured in all four registries. The DNR, NDA and NDR also contain wider prescription data, diagnosis data (cardiovascular disease, retinopathy) and mortality data. The DPV registry does not contain these data but contains detailed data on continuous glucose monitor and insulin pump usage. Differences in the methodologies employed and data fields collected were identified, including in data collection techniques, linkage processes, follow‐up protocols and the range of variables recorded. Even with this diversity in data collection, there remains a significant opportunity to perform collaborative analysis between the registries. By combining RWD collected in different populations and health care systems with diverse demographics, the transferability of evidence will increase, enabling research studies to be more representative and inclusive of diverse populations. Conclusion: The four registries that make up the REDDIE project contain many commonly collected variables. However, each registry presents specific strengths and limitations. By including all four databases, the REDDIE project benefits from the complementary strengths of each database.
- 1 October 2025
- Published by Wiley in Diabetic Medicine
- Vol. 42 (11) , e70112
Open AccessA cohort description and comparison of four European national diabetes registries for the REDDIE project
Aims: The Real‐world Evidence for Decisions in Diabetes (REDDIE) project aims to better understand how to use real‐world data (RWD) to advance research related to diabetes. To achieve this aim, four national registries (National Diabetes Audit (NDA (England)), Diabetes Patienten Verlaufsdokumentation (DPV (Germany)), Swedish National Registries (NDR), Danish National Registries (DNR)) are contributing data to the REDDIE project. This publication aims to describe the four registries and compare their unique strengths and limitations. Methods: Data regarding the four registries were extracted from their inception until 2024. Data regarding demographics, prescriptions, outcomes, lifestyle and diabetes‐specific variables (usage of continuous glucose monitors) were summarised. Results: A core set of variables was identified across all four registries in the REDDIE project. Demographic information, diabetes‐related medication, measures of glycaemic control and lifestyle factors are measured in all four registries. The DNR, NDA and NDR also contain wider prescription data, diagnosis data (cardiovascular disease, retinopathy) and mortality data. The DPV registry does not contain these data but contains detailed data on continuous glucose monitor and insulin pump usage. Differences in the methodologies employed and data fields collected were identified, including in data collection techniques, linkage processes, follow‐up protocols and the range of variables recorded. Even with this diversity in data collection, there remains a significant opportunity to perform collaborative analysis between the registries. By combining RWD collected in different populations and health care systems with diverse demographics, the transferability of evidence will increase, enabling research studies to be more representative and inclusive of diverse populations. Conclusion: The four registries that make up the REDDIE project contain many commonly collected variables. However, each registry presents specific strengths and limitations. By including all four databases, the REDDIE project benefits from the complementary strengths of each database.
- 1 January 2025
- Published by Human Kinetics in Journal for the Measurement of Physical Behaviour
- Vol. 8 (1)
How Many Days of Commercial Wearable Monitor Data Reflect Habitual Steps per Day? Insights From 9 Weeks Continuous Data in People Living With Diabetes
Understanding how many days of wearable device monitoring are needed to accurately reflect habitual behavior is important when aiming to assess population activity levels, both in research and public health contexts. However, few studies have focused on data collected from commercial wearables and on more interpretable metrics such as daily step count. Therefore, we investigated the number of days required to achieve a good level of reliability (intraclass correlation coefficient [ICC] ≥ .8) in group-level habitual daily step count using data collected in a sample of 239 people living with diabetes who wore a Fitbit Charge 4 consecutively for at least 9 weeks. Subgroup analyses also included assessments of reliability by average step count, variability in step count, diabetes type, sex, and age. Results of the Spearman–Brown analyses revealed that 7 days of monitoring was found to obtain an ICC value ≥ .9 in the overall sample, with 4 days of monitoring providing a reliability of ≥.8. All subgroups required 7 days for an ICC of ≥ .8 and 16 days for an ICC of ≥ .9. Additional analyses revealed that having low intraindividual variability in step count is an important factor in reducing the number of days required to meet acceptable reliability. Therefore, measures of intraindividual or within-person variability should be included alongside calculations of average daily steps to determine the potential reliability of group level estimates.
- 1 January 2025
- Published by Human Kinetics in Journal for the Measurement of Physical Behaviour
- Vol. 8 (1)
How Many Days of Commercial Wearable Monitor Data Reflect Habitual Steps per Day? Insights From 9 Weeks Continuous Data in People Living With Diabetes
Understanding how many days of wearable device monitoring are needed to accurately reflect habitual behavior is important when aiming to assess population activity levels, both in research and public health contexts. However, few studies have focused on data collected from commercial wearables and on more interpretable metrics such as daily step count. Therefore, we investigated the number of days required to achieve a good level of reliability (intraclass correlation coefficient [ICC] ≥ .8) in group-level habitual daily step count using data collected in a sample of 239 people living with diabetes who wore a Fitbit Charge 4 consecutively for at least 9 weeks. Subgroup analyses also included assessments of reliability by average step count, variability in step count, diabetes type, sex, and age. Results of the Spearman–Brown analyses revealed that 7 days of monitoring was found to obtain an ICC value ≥ .9 in the overall sample, with 4 days of monitoring providing a reliability of ≥.8. All subgroups required 7 days for an ICC of ≥ .8 and 16 days for an ICC of ≥ .9. Additional analyses revealed that having low intraindividual variability in step count is an important factor in reducing the number of days required to meet acceptable reliability. Therefore, measures of intraindividual or within-person variability should be included alongside calculations of average daily steps to determine the potential reliability of group level estimates.
- Open Access
- 19 July 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25, e45599
Accelerometer-Measured Physical Activity Data Sets (Global Physical Activity Data Set Catalogue) That Include Markers of Cardiometabolic Health: Systematic Scoping Review
Background: Cardiovascular disease accounts for 17.9 million deaths globally each year. Many research study data sets have been collected to answer questions regarding the relationship between cardiometabolic health and accelerometer-measured physical activity. This scoping review aimed to map the available data sets that have collected accelerometer-measured physical activity and cardiometabolic health markers. These data were then used to inform the development of a publicly available resource, the Global Physical Activity Data set (GPAD) catalogue. Objective: This review aimed to systematically identify data sets that have measured physical activity using accelerometers and cardiometabolic health markers using either an observational or interventional study design. Methods: Databases, trial registries, and gray literature (inception until February 2021; updated search from February 2021 to September 2022) were systematically searched to identify studies that analyzed data sets of physical activity and cardiometabolic health outcomes. To be eligible for inclusion, data sets must have measured physical activity using an accelerometric device in adults aged ≥18 years; a sample size >400 participants (unless recruited participants in a low- and middle-income country where a sample size threshold was reduced to 100); used an observational, longitudinal, or trial-based study design; and collected at least 1 cardiometabolic health marker (unless only body mass was measured). Two reviewers screened the search results to identify eligible studies, and from these, the unique names of each data set were recorded, and characteristics about each data set were extracted from several sources. Results: A total of 17,391 study reports were identified, and after screening, 319 were eligible, with 122 unique data sets in these study reports meeting the review inclusion criteria. Data sets were found in 49 countries across 5 continents, with the most developed in Europe (n=53) and the least in Africa and Oceania (n=4 and n=3, respectively). The most common accelerometric brand and device wear location was Actigraph and the waist, respectively. Height and body mass were the most frequently measured cardiometabolic health markers in the data sets (119/122, 97.5% data sets), followed by blood pressure (82/122, 67.2% data sets). The number of participants in the included data sets ranged from 103,712 to 120. Once the review processes had been completed, the GPAD catalogue was developed to house all the identified data sets. Conclusions: This review identified and mapped the contents of data sets from around the world that have collected potentially harmonizable accelerometer-measured physical activity and cardiometabolic health markers. The GPAD catalogue is a web-based open-source resource developed from the results of this review, which aims to facilitate the harmonization of data sets to produce evidence that will reduce the burden of disease from physical inactivity.
- 19 July 2023
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 25, e45599
Open AccessAccelerometer-Measured Physical Activity Data Sets (Global Physical Activity Data Set Catalogue) That Include Markers of Cardiometabolic Health: Systematic Scoping Review
Background: Cardiovascular disease accounts for 17.9 million deaths globally each year. Many research study data sets have been collected to answer questions regarding the relationship between cardiometabolic health and accelerometer-measured physical activity. This scoping review aimed to map the available data sets that have collected accelerometer-measured physical activity and cardiometabolic health markers. These data were then used to inform the development of a publicly available resource, the Global Physical Activity Data set (GPAD) catalogue. Objective: This review aimed to systematically identify data sets that have measured physical activity using accelerometers and cardiometabolic health markers using either an observational or interventional study design. Methods: Databases, trial registries, and gray literature (inception until February 2021; updated search from February 2021 to September 2022) were systematically searched to identify studies that analyzed data sets of physical activity and cardiometabolic health outcomes. To be eligible for inclusion, data sets must have measured physical activity using an accelerometric device in adults aged ≥18 years; a sample size >400 participants (unless recruited participants in a low- and middle-income country where a sample size threshold was reduced to 100); used an observational, longitudinal, or trial-based study design; and collected at least 1 cardiometabolic health marker (unless only body mass was measured). Two reviewers screened the search results to identify eligible studies, and from these, the unique names of each data set were recorded, and characteristics about each data set were extracted from several sources. Results: A total of 17,391 study reports were identified, and after screening, 319 were eligible, with 122 unique data sets in these study reports meeting the review inclusion criteria. Data sets were found in 49 countries across 5 continents, with the most developed in Europe (n=53) and the least in Africa and Oceania (n=4 and n=3, respectively). The most common accelerometric brand and device wear location was Actigraph and the waist, respectively. Height and body mass were the most frequently measured cardiometabolic health markers in the data sets (119/122, 97.5% data sets), followed by blood pressure (82/122, 67.2% data sets). The number of participants in the included data sets ranged from 103,712 to 120. Once the review processes had been completed, the GPAD catalogue was developed to house all the identified data sets. Conclusions: This review identified and mapped the contents of data sets from around the world that have collected potentially harmonizable accelerometer-measured physical activity and cardiometabolic health markers. The GPAD catalogue is a web-based open-source resource developed from the results of this review, which aims to facilitate the harmonization of data sets to produce evidence that will reduce the burden of disease from physical inactivity.